On-Demand Webinar: Integrating Octet® BLI into Early Antibody Discovery Workflows
As industry-wide advancements in antibody drug discovery continue to push toward larger panels of candidates for early-stage characterization, more efficient identification of lead molecules through enhanced screening resolution is required. Integrating instruments like the Octet® into the overall characterization workflow enables reliable, high throughput selection of lead candidates more effectively than alternative traditional techniques. This presentation will highlight a few unique methods of Octet® utilization as a replacement or supplemental tool for various antibody discovery protocols. Comparisons across platforms, including traditional ELISA, flow cytometry, surface plasmon resonance, and in vivo studies will be presented.
- Improve the overall drug discovery process to increase the success rate of preclinical candidates
- Identify elite candidates earlier in screening
- Use of the Octet® platform in high-throughput, high-resolution screening for selection of lead candidates
Colby Souders, PhD | Chief Scientific Officer | Abveris
After his PhD in Cell and Molecular Biology from Texas A&M, Colby Souders joined MassBiologics of the University of Massachusetts Medical School as a Scientist in the Product Discovery department before becoming Assistant Professor of Medicine. At MassBiologics, he lead multiple programs to discover and advance monoclonal antibodies for the prevention, treatment or diagnosis of various infectious and endogenous diseases, while also developing related platform technologies to expand the MassBiologics pipeline. In 2016, he joined the Kanyos Bio Protein Engineering team (now Anokion) to develop therapeutics based on a novel antigen-specific immune tolerance platform. After completing multiple antibody discovery, affinity maturation and protein engineering campaigns at Kanyos, Colby joined Abveris Antibody as Chief Technology Officer to usher in a new generation of antibody discovery tools and build a premium discovery engine. Currently as Chief Scientific Officer, Colby and the entire Abveris team have rapidly expanded capabilities while reducing timelines for antibody discovery projects.